Net sales rose 15% year-over-year with a 52% gross margin, while the divestment of CyberGene marks a strategic shift toward diagnostics distribution. The sale strengthens the balance sheet but will lower future revenue and margin base.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.